Annual report 2024: ALK delivers 15% sales growth with profits up 65%

Read more about Annual report 2024: ALK delivers 15% sales growth with profits up 65%

Link

https://www.globenewswire.com/news-release/2025/02/19/3028468/0/en/Annual-repor…

Created date

Wed, 02/19/2025 - 12:00

Nasdaq ID

3028468

Last updated: 2025.03.24

Annual General Meeting in ALK-Abelló A/S on 13 March 2025

Read more about Annual General Meeting in ALK-Abelló A/S on 13 March 2025

Link

https://www.globenewswire.com/news-release/2025/02/19/3028793/0/en/Annual-Gener…

Created date

Wed, 02/19/2025 - 12:00

Nasdaq ID

3028793

Last updated: 2025.03.24

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

Read more about Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

Link

https://www.globenewswire.com/news-release/2025/02/21/3030519/0/en/Report-on-tr…

Created date

Fri, 02/21/2025 - 12:00

Nasdaq ID

3030519

Last updated: 2025.03.24

Annual General Meeting in ALK-Abelló A/S held on 13 March 2025

Read more about Annual General Meeting in ALK-Abelló A/S held on 13 March 2025

Link

https://www.globenewswire.com/news-release/2025/03/13/3042490/0/en/Annual-Gener…

Created date

Thu, 03/13/2025 - 12:00

Nasdaq ID

3042490

Last updated: 2025.03.13

ACARIZAX® approved in Canada for treatment of young children

Read more about ACARIZAX® approved in Canada for treatment of young children

Link

https://www.globenewswire.com/news-release/2025/03/07/3038942/0/en/ACARIZAX-app…

Created date

Fri, 03/07/2025 - 12:00

Nasdaq ID

3038942

Last updated: 2025.03.07

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

Read more about Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

Link

https://www.globenewswire.com/news-release/2025/03/04/3036986/0/en/Report-on-tr…

Created date

Tue, 03/04/2025 - 12:00

Nasdaq ID

3036986

Last updated: 2025.03.04

FDA approves ODACTRA® for the treatment of house dust mite allergy in young children

Read more about FDA approves ODACTRA® for the treatment of house dust mite allergy in young children

Link

https://www.globenewswire.com/news-release/2025/02/27/3034245/0/en/FDA-approves…

Created date

Thu, 02/27/2025 - 12:00

Nasdaq ID

3034245

Last updated: 2025.02.27

Invitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025

Read more about Invitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025

Link

https://www.globenewswire.com/news-release/2025/02/12/3025225/0/en/Invitation-t…

Created date

Wed, 02/12/2025 - 12:00

Nasdaq ID

3025225

Last updated: 2025.02.12

ALK’s house dust mite tablet (ACARIZAX®) now recommended by NICE for use in the UK health system

Read more about ALK’s house dust mite tablet (ACARIZAX®) now recommended by NICE for use in the UK health system

Link

https://www.globenewswire.com/news-release/2025/01/30/3017756/0/en/ALK-s-house-…

Created date

Thu, 01/30/2025 - 12:00

Nasdaq ID

3017756

Last updated: 2025.01.30

ALK Christmas Party

GO BACK TO NEWS

Last updated: 2024.12.17

Subscribe to